Seno Medical Instruments Inc., based in San Antonio, Tex., has shared clinical data from a clinical study demonstrating that its Imagio breast imaging system can provide significant differentiation among prognostic subtypes of breast cancer. These prognostic subtypes offer important information about the genes that each patient’s cancer expresses.
“Confirming a diagnosis of breast cancer is just the first step in understanding the pathology of a patient’s tumor,” says study presenter Stephen Grobmyer, MD, director of breast surgical oncology at Cleveland Clinic. “Determining a patient’s prognostic subtype of breast cancer is essential for understanding how tumors will respond to specific therapies and selecting a treatment regimen that offers the patient the best chance of a positive outcome.”
For more information, visit Seno Medical Instruments.